Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomised, open, blinded-endpoint study of torasemide prolonged release vs furosemide to evaluate the efficacy on myocardial fibrosis in patients with heart failure

Trial Profile

Prospective, randomised, open, blinded-endpoint study of torasemide prolonged release vs furosemide to evaluate the efficacy on myocardial fibrosis in patients with heart failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Torasemide (Primary) ; Furosemide
  • Indications Chronic heart failure
  • Focus Pharmacodynamics
  • Acronyms TORAFIC
  • Sponsors Ferrer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Sep 2011 Results published in the Clinical Therapeutics.
    • 29 Aug 2009 Trial design and baseline characteristics presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top